285 related articles for article (PubMed ID: 30105931)
1. Radioiodine Refractory Differentiated Thyroid Cancer: Time to Update the Classifications.
Van Nostrand D
Thyroid; 2018 Sep; 28(9):1083-1093. PubMed ID: 30105931
[TBL] [Abstract][Full Text] [Related]
2. Advanced differentiated thyroid cancer: when to stop radioiodine?
Giovanella L; van Nostrand D
Q J Nucl Med Mol Imaging; 2019 Sep; 63(3):267-270. PubMed ID: 31271271
[TBL] [Abstract][Full Text] [Related]
3. Radioiodine refractory differentiated thyroid cancer.
Jin Y; Van Nostrand D; Cheng L; Liu M; Chen L
Crit Rev Oncol Hematol; 2018 May; 125():111-120. PubMed ID: 29650270
[TBL] [Abstract][Full Text] [Related]
4. TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer.
Yang X; Li J; Li X; Liang Z; Gao W; Liang J; Cheng S; Lin Y
J Nucl Med; 2017 Feb; 58(2):258-265. PubMed ID: 27493271
[TBL] [Abstract][Full Text] [Related]
5. Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas.
Wassermann J; Bernier MO; Spano JP; Lepoutre-Lussey C; Buffet C; Simon JM; Ménégaux F; Tissier F; Leban M; Leenhardt L
Oncologist; 2016 Jan; 21(1):50-8. PubMed ID: 26675742
[TBL] [Abstract][Full Text] [Related]
6. Ten Year Experience of Radioiodine Dosimetry: is it Useful in the Management of Metastatic Differentiated Thyroid Cancer?
Sun F; Gerrard GE; Roberts JK; Telford T; Namini S; Waller M; Flux G; Gill VM
Clin Oncol (R Coll Radiol); 2017 May; 29(5):310-315. PubMed ID: 28132755
[TBL] [Abstract][Full Text] [Related]
7. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
8. The medical treatment of radioiodine-refractory differentiated thyroid cancers in 2019. A TUTHYREF
de la Fouchardiere C; Alghuzlan A; Bardet S; Borget I; Borson Chazot F; Do Cao C; Godbert Y; Leenhardt L; Zerdoud S; Leboulleux S
Bull Cancer; 2019 Sep; 106(9):812-819. PubMed ID: 31200896
[TBL] [Abstract][Full Text] [Related]
9. Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance.
Shen H; Zhu R; Liu Y; Hong Y; Ge J; Xuan J; Niu W; Yu X; Qin JJ; Li Q
Drug Resist Updat; 2024 Jan; 72():101013. PubMed ID: 38041877
[TBL] [Abstract][Full Text] [Related]
10. Radioiodine for High Risk and Radioiodine Refractory Thyroid Cancer: Current Concepts in Management.
Newbold KL; Flux G; Wadsley J
Clin Oncol (R Coll Radiol); 2017 May; 29(5):307-309. PubMed ID: 28139379
[TBL] [Abstract][Full Text] [Related]
11. Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan.
Chao M
Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):438-47. PubMed ID: 20561773
[TBL] [Abstract][Full Text] [Related]
12. Differentiated Thyroid Cancer-Treatment: State of the Art.
Schmidbauer B; Menhart K; Hellwig D; Grosse J
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28629126
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review.
Maghsoomi Z; Emami Z; Malboosbaf R; Malek M; Khamseh ME
BMC Cancer; 2021 May; 21(1):579. PubMed ID: 34016077
[TBL] [Abstract][Full Text] [Related]
14. [Radioiodine therapy and radioiodine after-care in differentiated thyroid gland carcinomas].
Börner AR; Müller-Gärtner HW
Zentralbl Chir; 1997; 122(4):274-85. PubMed ID: 9221638
[TBL] [Abstract][Full Text] [Related]
15. 99mTc-EDDA/HYNIC-TOC in the diagnosis of differentiated thyroid carcinoma refractory to radioiodine treatment.
Czepczyński R; Gryczyńska M; Ruchała M
Nucl Med Rev Cent East Eur; 2016; 19(2):67-73. PubMed ID: 27479883
[TBL] [Abstract][Full Text] [Related]
16. Differentiated thyroid cancer: Case report of false positive
Giannoula E; Koutsouki G; Exadaktylou P; Papadopoulos N; Papanastasiou E; Doumas A; Iakovou I
Hell J Nucl Med; 2023; 26(1):66-69. PubMed ID: 37031423
[TBL] [Abstract][Full Text] [Related]
17. Radioiodine therapy of advanced differentiated thyroid cancer: clinical considerations and multidisciplinary approach.
Giovanella L; Scappaticcio L
Q J Nucl Med Mol Imaging; 2019 Sep; 63(3):229-234. PubMed ID: 31271270
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic 123I and 131I activities and radioiodine therapy. Effects on urinary iodine excretion in patients with differentiated thyroid carcinoma.
Meller B; von Hof K; Genina E; Deisting W; Meller J; Richter E; Baehre M
Nuklearmedizin; 2005; 44(6):243-8. PubMed ID: 16400384
[TBL] [Abstract][Full Text] [Related]
19. Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead.
Satapathy S; Bal C
Front Endocrinol (Lausanne); 2022; 13():924841. PubMed ID: 35903277
[TBL] [Abstract][Full Text] [Related]
20. Integrated metabolic and genetic analysis reveals distinct features of human differentiated thyroid cancer.
Cararo Lopes E; Sawant A; Moore D; Ke H; Shi F; Laddha S; Chen Y; Sharma A; Naumann J; Guo JY; Gomez M; Ibrahim M; Smith TL; Riedlinger GM; Lattime EC; Trooskin S; Ganesan S; Su X; Pasqualini R; Arap W; De S; Chan CS; White E
Clin Transl Med; 2023 Jun; 13(6):e1298. PubMed ID: 37317665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
